Clinical Trials Logo

Filter by:
NCT ID: NCT01819181 Completed - Clinical trials for Symptomatic Aortic Stenosis

Women's INternational Transcatheter Aortic Valve Implantation Registry

WINTAVI
Start date: March 2013
Phase:
Study type: Observational [Patient Registry]

The study will evaluate all female patients with severe aortic stenosis undergoing transcatheter valve implantation with commercially available valves and delivery systems.

NCT ID: NCT01818817 Completed - Breast Cancer Clinical Trials

Ultrasound Paravertebral Block in Breast Surgery.

Start date: November 2011
Phase: N/A
Study type: Observational

The purpouse of the study is to determine wether Ultrasound Guided,Ens-assisted paravertebral block with single shot is a safe and reliable anesthetic technique in breast surgery.

NCT ID: NCT01818752 Completed - Multiple Myeloma Clinical Trials

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

CLARION
Start date: July 8, 2013
Phase: Phase 3
Study type: Interventional

The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade® (bortezomib), melphalan and prednisone (VMP).

NCT ID: NCT01818544 Completed - Bronchiectasis Clinical Trials

Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis

Start date: April 2013
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of 28 day oral administration of BAY85-8501 versus placebo in subjects with non-CF Bronchiectasis (BE). The secondary objectives are to examine the effect of BAY85-8501 on pulmonary function, biomarkers of inflammation and tissue damage, and the impact on overall health and perceived well-being and to evaluate the pharmacokinetics of BAY85-8501.

NCT ID: NCT01818492 Completed - Clinical trials for Primary Haemophagocytic Lymphohistiocytosis

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

Start date: July 2013
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and efficacy of a new drug aimed at controlling disease activity in patients diagnosed with primary haemophagocytic lymphohistiocytosis. The new drug can be administered as the first-line therapy, to patients not previously treated with the current standard of care, or can be given to patients who have either failed or were unable to tolerate the current standard of care. Administration will be on top of a glucocorticosteroid, which is usually part of the current recommended treatment.

NCT ID: NCT01818115 Completed - Clinical trials for Primary Open Angle Glaucoma

Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.

Hydrus II
Start date: January 2011
Phase: N/A
Study type: Interventional

The objective of this study is to demonstrate the ability of the Hydrus Implant to lower intraocular pressure in glaucoma patients undergoing cataract surgery.

NCT ID: NCT01817959 Completed - Clinical trials for Islet Transplantation in Diabetes Mellitus Type 1

Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation

REP0211
Start date: October 2012
Phase: Phase 3
Study type: Interventional

The objective of this clinical trial was: - to assess whether Reparixin leads to improved transplant outcome as measured by glycaemic control following intra-hepatic infusion of pancreatic islets in patients with Type 1 diabetes (T1D). The safety of Reparixin in the specific clinical setting was also evaluated. Background: The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after organ transplantation. Reparixin is the first low molecular weight blocker of CXCL8 biological activity in clinical development. Thus, the use of reparixin may emerge as a potential key component in the sequentially integrated approach to immunomodulation and control of non specific inflammatory events surrounding the early phases of pancreatic islet transplantation in T1D patients.

NCT ID: NCT01817647 Completed - Anastomotic Leak Clinical Trials

PREDICS Study: PCT Reveals Early Dehiscence in Colorectal Surgery

PREDICS
Start date: December 2012
Phase: N/A
Study type: Observational [Patient Registry]

Procalcitonin (PCT) is a biomarker used to monitor serious bacterial infections and guide antibiotic therapy. Anastomotic leak (AL) after colorectal surgery is a severe complication associated with relevant short and long-term sequelae. The aim of our study is to assess the predictive value of PCT level for early diagnosis of anastomotic leak after colorectal surgery.

NCT ID: NCT01816295 Completed - Hypogonadism Clinical Trials

A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

Start date: May 2013
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate if testosterone solution can raise testosterone hormone levels into the normal range, and also improve levels of sexual arousal, interest and drive and/or energy level, in men with low testosterone and decreased sexual arousal, interest and drive and/or decreased energy. The study will last about 16 weeks, followed by an optional 24 week open label treatment phase to investigate the long term safety of testosterone solution.

NCT ID: NCT01816282 Completed - Clinical trials for Osteoarthritis of the Knee

The Use of Fibrin Sealant to Reduce Bleeding After Total Knee Replacement

Start date: March 2011
Phase: N/A
Study type: Interventional

A randomized controlled study is performed to address the question of whether the topical application of a novel fibrin sealant, Evicel (Johnson & Johnson Wound Management, Ethicon, Somerville, NJ) in patient undergoing total knee replacement (TKR) reduce the perioperative blood loss and the need for allogenic blood transfusion compared to a control group. We hypothesize that fibrin sealant decrease the drop in post-operative hemoglobin level after total knee replacement.